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ABSTRACT
The aim of this study was to reduce barriers that prevent implementation of evidence-based
recommendations about single-fraction palliative radiotherapy (PRT) and to demonstrate that
single-fraction PRT yields similar outcomes as long-course treatment (≥10 fractions) in patients
with bone metastases from breast cancer. This retrospective study (2007–2014) included 118
Norwegian female patients. All patients received guideline-conform systemic therapy including
bone-targeting agents. Median survival was 12.7 months. Long-course PRT was prescribed in 60%
of patients, while 21% had PRT with a single fraction of 8 Gy to at least one target. Reirradiation
rate was not significantly higher after 8 Gy (9%, compared to 5% after long-course PRT and 6%
after 4 Gy x5). Patients with favorable baseline characteristics such as younger age and good
performance status (PS) were significantly more likely to receive long-course PRT. Biological
subtype and comorbidity did not correlate with fractionation. Prognosis was influenced by
biological subtype, extra-skeletal disease extent, severe anemia and abnormal CRP. The limited
need for reirradiation after single fraction PRT might encourage physicians to prescribe this
convenient regimen, which would improve resource utilization. Even patients with PS3 had a
median survival of 3 months, which indicates that they could experience worthwhile clinical
benefit.
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Skeletal-related events (SRE) are common in patients with
bone metastases from breast cancer [1–4]. The term SRE
relates to pathological fractures, orthopaedic surgery,
spinal cord compression and utilisation of radiotherapy.
Jensen et al. estimated the incidence of bone metastases
and SRE in newly diagnosed breast cancer patients in
Denmark from 1999 to 2007 using the Danish National
Patient Registry [5]. Of the 35,912 patients with breast
cancer, 178 (0.5%) presented with bone metastases at the
time of primary breast cancer diagnosis, and of these, 43%
developed an SRE during follow-up. A total of 1,272 of
35,690 (3.6%) patients without bone metastases at diag-
nosis developed early bone metastases, i.e. during a med-
ian follow-up time of 3.4 years. Among these patients, 46%
subsequently developed an SRE. The 5-year survival rate of
Danish patients with bone metastases was 8% [6].
Radiotherapy for painful uncomplicated bone
metastases is more common than radiotherapy for
spinal cord compression or after orthopaedic stabilisa-
tion of fractures [4]. Multiple randomised studies
suggest equivalent pain relief from bone metastases
after radiotherapy with long-course regimens (≥10
fractions) and shorter courses [7–11]. Although
American Society for Radiation Oncology evidence-
based guidelines and the Choosing Wisely campaign
endorse single-fraction treatments and caution
against the use of extended courses, publications
report modest single-fraction utilisation rates [12,13].
In the case of breast cancer with comparatively
favourable survival rates, clinicians might overrate
the importance of local control as a function of higher
biologically equivalent dose in the era of effective
systemic treatment. They might be reluctant to pre-
scribe shorter courses because of the higher rates of
reirradiation reported in previous studies [8] and a
fear of skeletal complications from insufficiently con-
trolled metastases. The purpose of the present retro-
spective quality of care audit is to compare patients
who received long-course and short-course regimens,
and to reduce barriers that prevent implementation of
evidence-based recommendations. The latter is
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especially important in rural areas with large travel
distance and challenging winter climate.
Material and methods
Patients and treatment
This retrospective intention-to-treat study included 118
consecutive female patients with bone metastases from
breast cancer who received palliative external beam
radiotherapy at the authors’ institution in Bodø (aca-
demic teaching hospital in rural North Norway). All
patients were treated with linear accelerators between
2007 and 2014 after two- or three-dimensional treat-
ment planning. Some patients presented with bone
metastases at first cancer diagnosis, others later during
the disease trajectory, and all had histological confirma-
tion of malignancy. Systemic treatment was given
according to the guidelines of the Norwegian Breast
Cancer Group, which are stratified by biological subtype
and available online. While single-fraction irradiation
was recommended for uncomplicated bone metastases,
final decision-making was left to the discretion of the
treating physician. Nationwide, the proportion of sin-
gle-fraction treatments has increased from 16% in 1997
to 41% in 2007 [14]. Radionuclide treatment was not
utilised in this patient cohort.
Blood tests
Serum lactate dehydrogenase (LDH), albumin, haemo-
globin, C-reactive protein (CRP), calcium and alkaline
phosphatase (ALP) were part of routine blood chemistry
and imaging assessment in patients with metastatic
breast cancer. However, some patients had missing
values. The hospital’s electronic patient record system
was used to collect all follow-up and baseline data
including blood tests. The latter had to be no older
than 2 weeks before the first fraction of radiotherapy.
Elevated LDH was defined as ≥205 U/l according to the
hospitals’ reference value (low albumin <34 g/l; high
ALP ≥105 U/l; high calcium >2.55 mmol/l; normal CRP
<5 mg/l; low haemoglobin <11.7 g/dl; blood transfusion
was given if haemoglobin was <10 g/dl).
Statistical methods
Actuarial survival from the first day of radiotherapy was
calculated with the Kaplan–Meier method and com-
pared between subgroups with differing baseline char-
acteristics including, but not limited to, performance
status, biological subtype and patterns of metastatic
disease with the log-rank test. If the p-value was
≤0.05, the corresponding baseline characteristic was
included in the multivariate analysis of prognostic fac-
tors for survival, which consisted of Cox regression
(backward conditional method). Associations between
different variables of interest were assessed with the
chi-square or Fisher exact probability test (two-tailed). A
p-value ≤0.05 was considered statistically significant.
Results
Patient characteristics
While 17 patients (15%) had bone metastases at initial
diagnosis or de novo stage IV disease, the vast majority
presented with metastatic disease at later time points.
The median age of all patients was 61 years (range
33–87 years). The median time interval from the initial
diagnosis of breast cancer was 57 months (range
1–384 months) and the median time interval from
metastatic disease, irrespective of site, to palliative
radiotherapy for bone metastases was 7 months
(range 1–180 months). Further patient characteristics
are shown in Table 1.
Treatment details
Few patients (5%) received more than 10 fractions. The
most common fractionation regimen was 10 fractions
of 3 Gy (55%) followed by 5 fractions of 4 Gy (24%) and
8 Gy single fraction (16%). The proportion of patients
treated with long-course radiotherapy remained
unchanged over time. Fifty patients (42%) had spinal
target volumes, but only 8% had a diagnosis of meta-
static spinal cord compression (MSCC). Forty-two
patients (36%) received simultaneous radiotherapy to
two target volumes and 16 (14%) to at least three
target volumes. The vast majority of patients with
more than one target volume received the same frac-
tionation regime for all volumes. However, 8 patients
with differing regimes had both long and short-course
radiotherapy during the same treatment course.
Therefore, 25 patients (21%) had at least one target
volume that was treated with a single fraction of 8 Gy.
Eighteen patients (15%) entering the study received
reirradiation to a previously treated skeletal target
volume. All but one patient completed their prescribed
course of radiotherapy.
Factors associated with prescription of long-course
radiotherapy
As shown in Table 2, significantly more patients with
favourable baseline characteristics received long-
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course regimens. These characteristics included
absence of lung metastases (hazard ratio (HR) with
95% confidence interval 1.85 (1.21–2.83)) and/or
pleural metastases/effusion (HR 1.82 (1.18–2.82)), nor-
mal serum haemoglobin (HR 2.43 (1.43–4.15)), CRP
(HR 1.64 (1.20–2.26)), LDH (HR 1.64 (1.22–2.21)) and
albumin (HR 2.41 (1.13–5.15)), i.e. surrogate markers of
disease extent, early radiotherapy within 6 months
from diagnosis of metastatic disease (HR 1.71 (1.19–
2.45)), age younger than 65 years (HR 1.43 (1.02–
2.00)), and good performance status (Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus 0–1) (HR 1.75 (1.22–2.52)). Biological subtype
(HER2 and oestrogen receptor status), comorbidity
and treatment of spinal/multiple target volumes
were not associated with fractionation regimen.
Reirradiation of target volumes irradiated for the
first time in the context of this study
Since 18 out of all 118 patients included in this study
received reirradiation prior to entering the study, we
excluded these patients from the analysis of reirradia-
tion during follow-up. The remaining 100 patients
received radiotherapy to a total of 154 target volumes.
The proportions of reirradiated patients were low and
not significantly associated with fractionation regimen
(9% after single-fraction PRT, 5% after long-course PRT
and 6% after 4 Gy ×5, p=0.4 and 1.0, respectively).
There was no need for orthopaedic surgery in irradiated
regions during follow-up.
Overall survival
Twenty-five patients were alive at last follow-up (15
June 2015) with a median follow-up of 28 months.
Date of death was known in all other patients. Median
survival was 12.7 months and 22% of the patients
were alive after 3 years (Figure 1). Five patients (4%)
received radiotherapy in the last 30 days of life and
13 (11%) in the last 2 months. Median survival from
initial diagnosis of metastatic disease was 20 months.
Of all parameters shown in Table 1 or reported in the
results section, 6 were found to be independent prog-
nostic factors for survival after radiotherapy in multi-
variate Cox regression analysis: absence of extra-
skeletal metastases (p=0.0001), no pleural metas-
tases/effusion (p=0.0001), CRP <5 mg/l (p=0.0001),
positive oestrogen receptor (p=0.001), no lung metas-
tases (p=0.001), no need for blood transfusion
because of anaemia (p=0.048). Radiotherapy-related
parameters such as fractionation were not statistically
significant. Neither was performance status. Even
patients with ECOG performance status 3 had a med-
ian survival of 3 months.
Discussion
We performed a comprehensive analysis of fractiona-
tion patterns and clinical endpoints including reirradia-
tion rate and survival after radiotherapy for bone
metastases from breast cancer. In our country’s publicly
funded healthcare system all patients have equal access
to treatment with full reimbursement of travel and
Table 1. Patient characteristics before radiotherapy (RT), n = 118.
Parameter n %
Triple negativea 22 20
ER positive HER2 negativea 68 62
ER negative HER2 positivea 5 5
ER and HER2 positivea 15 14
Metastases at first diagnosisa 17 15
Metachronous metastatic diseasea 98 85
Interval from met. disease to RT ≤6 moa 56 49
Interval from met. disease to RT >6 moa 59 51
No extra-skeletal visceral metastases 57 48
Visceral metastases 61 52
Liver metastases 36 31
No liver metastases 82 69
Lung metastases 38 32
No lung metastases 80 68
Pleural metastases/effusion 19 16
No pleural metastases/effusion 98 84
Metastatic spinal cord compression 10 8
No metastatic spinal cord compression 108 92
ECOG PS 0 32 27
ECOG PS 1 38 32
ECOG PS 2 32 27
ECOG PS 3–4 16 14
Charlson comorbidity index 0a 58 52
Charlson comorbidity index ≥1a 53 48
Age <65 years 70 59
Age ≥65 years 48 41
Spinal target volume 50 42
No spinal target volume 68 58
Only one target volume 60 51
More than one target volume 58 49
Reirradiation 18 15
No reirradiation 100 85
Serum albumin normala 94 84
Serum albumin lowa 18 16
Serum LDH normala 45 45
Serum LDH higha 56 55
Serum ALP normala 47 45
Serum ALP higha 58 55
Serum CRP normala 55 50
Serum CRP higha 56 50
Haemoglobin normala 80 71
Haemoglobin lowa 33 29
Received blood transfusion before RT 9 8
No blood transfusion 109 92
Hypercalcemiaa 10 8
No hypercalcemiaa 101 91
Non-opioid analgesicsa 74 69
Opioid analgesicsa 33 31
Steroidsa 31 30
No steroidsa 72 70
a information not available in all patients
ER: oestrogen receptor; ECOG PS: Eastern Cooperative Oncology Group
performance status; LDH: lactate dehydrogenase; ALP: alkaline phospha-
tase; CRP: C-reactive protein
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housing expenses. Even in our rural area, the utilisation
of palliative radiotherapy did not vary with distance
between residence and hospital [15]. Approximately
60,000 inhabitants live within 60 km of the radiotherapy
facility and another 150,000 in remote areas (maximum
400 km) including small islands. Copayments for
chemo- or radiotherapy do not exist. Adherence to
national guidelines is excellent. Compared with other
countries, the proportion of single-fraction treatments
for bone metastases, 41% in 2007 for all tumour types
combined [14], was quite high. However, there were
substantial differences in the proportion of single-frac-
tion treatments between the treatment centres (range
25–54%). These differences persisted after adjustment
for sex, age, primary diagnosis, anatomical region, and
travel distance. Because of limited nationwide capacity
and lower than recommended general utilisation of
radiotherapy, waiting lists existed in all radiotherapy
departments despite operating at maximum capacity.
Because there is no reason to believe that patient
Table 2. Choice of fractionation stratified by baseline characteristics (n = 118).
Parameter n % <10 fractions (ITT) % ≥10 fractions (ITT) p-value
Triple negativea 22 36% 64%
ER positive HER2 negativea 68 35% 65%
ER negative HER2 positivea 5 20% 80%
ER and HER2 positivea 15 53% 47% 0.61b
Metastases at first diagnosisa 17 35% 65%
Metachronous metastatic diseasea 98 41% 59% 0.84
Interval from met. disease to RT ≤6 moa 56 27% 73%
Interval from met. disease to RT >6 moa 59 53% 47% 0.007
No extra-skeletal visceral metastases 57 33% 67%
Visceral metastases 61 46% 54% 0.28
Liver metastases 36 44% 56%
No liver metastases 82 38% 62% 0.76
Lung metastases 38 58% 42%
No lung metastases 80 31% 69% 0.017
Pleural metastases/effusion 19 64% 36%
No pleural metastases/effusion 98 35% 65% 0.038
Metastatic spinal cord compression 10 20% 80%
No metastatic spinal cord compression 108 42% 58% 0.27
ECOG PS 0 32 28% 72%
ECOG PS 1 38 26% 74%
ECOG PS 2 32 50% 50%
ECOG PS 3–4 16 75% 25% 0.01b
Charlson comorbidity index 0a 58 34% 66%
Charlson comorbidity index ≥1a 53 42% 58% 0.46
Age <65 years 70 31% 69%
Age ≥65 years 48 52% 48% 0.01
Spinal target volume 50 36% 64%
No spinal target volume 68 43% 57% 0.45
Only one target volume 60 35% 65%
More than one target volume 58 45% 55% 0.50
Reirradiation 18 61% 39%
No reirradiation 100 36% 64% 0.07
Serum albumin normala 94 33% 67%
Serum albumin lowa 18 72% 28% 0.007
Serum LDH normala 45 18% 82%
Serum LDH higha 56 50% 50% 0.003
Serum ALP normala 47 30% 70%
Serum ALP higha 58 43% 57% 0.21
Serum CRP normala 55 24% 76%
Serum CRP higha 56 54% 46% 0.002
Haemoglobin normala 80 26% 74%
Haemoglobin lowa 33 70% 30% 0.0001
Received blood transfusion before RT 9 67% 33%
No blood transfusion 109 38% 62% 0.22
Hypercalcemiaa 10 30% 70%
No hypercalcemiaa 101 40% 60% 0.36
Non-opioid analgesicsa 74 50% 50%
Opioid analgesicsa 33 27% 73% 0.06
Steroidsa 31 39% 61%
No steroidsa 72 42% 58% 0.81
a information not available in all patients
b p-value calculated over all strata
ER: oestrogen receptor; ITT: intention to treat; ECOG PS: Eastern Cooperative Oncology Group performance status;
LDH: lactate dehydrogenase; ALP: alkaline phosphatase; CRP: C-reactive protein
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characteristics differed to the same degree as single-
fraction utilisation rates, factors such as education and
local traditions might have played a role. Undoubtedly,
oncologists have to make individual decisions, which
may be influenced by different criteria. Ideally, they
would rely on objectively measurable validated para-
meters, which are related to the outcome of interest. In
the context of this study, we assumed that long-course
radiotherapy (≥10 fractions) should be reserved for a
minority of patients with bone metastases from breast
cancer, e.g. those with MSCC. We examined factors
associated with prescription of such regimens among
patients in our centre.
A typical patient in our study was a postmenopausal
woman with oestrogen receptor-positive and HER2-
negative disease who developed metachronous
uncomplicated bone metastases and continued on
state-of-the-art systemic therapy. According to the
national guidelines, such patients receive zoledronic
acid and several lines of sequential hormonal and cyto-
toxic therapy, depending on visceral tumour load,
response to previous therapy and other parameters.
We found that surprisingly many patients (60%) were
treated with long-course radiotherapy, and that these
figures had remained constant over time. Reirradiation
rate was numerically higher after single-fraction radio-
therapy (9%, compared with 5% after long-course ther-
apy and 6% after 5 fractions of 4 Gy), but these
differences were not statistically significant. Previous
studies that included patients with different primary
tumours reported reirradiation in 11–42% after a single
fraction and 0–24% after multiple fractions [8]. In our
study, orthopaedic surgery was not required in any
patient. No survival difference was evident either.
These findings suggest that short-course radiotherapy
is oncologically safe in the current era of effective sys-
temic therapy.
Limitations of this study include the number of
patients, statistical power of subgroup analyses, and
retrospective design. In a larger cohort of patients, the
different reirradiation rates might have reached the
level of statistical significance. Nevertheless, this would
not imply clinical relevance. Patients with favourable
baseline characteristics were significantly more likely
to receive long-course regimens. These characteristics
included absence of lung metastases and/or pleural
metastases/effusion, normal serum haemoglobin, CRP,
LDH and albumin (surrogate markers of disease extent),
early radiotherapy within 6 months from diagnosis of
metastatic disease, age younger than 65 years, and
good performance status (ECOG 0–1). Biological sub-
type (HER2 and oestrogen receptor status), comorbidity
and treatment of spinal/multiple target volumes did not
correlate with fractionation. A possible interpretation is
that clinicians are afraid of providing inadequate treat-
ment to the young, recently diagnosed and well-func-
tioning patients. It is necessary to confirm these results
in larger studies. There is currently no sufficient evi-
dence to suggest that local treatment improves the
survival time of patients with oligometastatic bone
Figure 1. Actuarial Kaplan–Meier survival curve for 118 patients with bone metastases from breast cancer (median 12.7 months).
Nearly 10% of the patients were still alive after 6 years.
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metastases who receive effective systemic therapy. In
order to change the observed pattern of care, physi-
cians need to be aware of the excellent results obtained
with short-course radiotherapy. Such treatment is also
adequate in elderly patients and those with limited
performance status, given that even patients with PS3
had a median survival of 3 months, which indicates that
they could experience worthwhile clinical benefit after
PRT. In other words, survival expectation in these sub-
groups is sufficiently long to warrant optimal pain con-
trol. Patients responding to radiotherapy commonly do
so within approximately 4 weeks [16,17].
Disease extent in patients with metastatic breast
cancer is highly variable, ranging from solitary bone
metastasis to widespread bone marrow involvement,
and often including extra-skeletal sides such as lung,
pleura, liver and lymph nodes [18]. Thus, survival of
these patients might vary from few months to several
years. We found a large number of patient and disease
characteristics to be associated with survival after radio-
therapy. These included, for example, breast cancer
type (shortest survival for triple negative status, median
5.5 months) and patterns of metastatic disease (longest
survival for bone-only disease, median 22.9 months),
but not age. Interestingly, performance status was less
important than other factors. A potential explanation
might be that poor performance status resulting from
bone pain often improves rapidly after radiotherapy.
Gebhardt et al. reported an effective method to
improve decision-making [19]. Their group implemented
a clinical pathway for the management of bone metas-
tases in 2003 that required the entry of management
decisions into an online tool that subjected off-pathway
choices to peer review beginning in 2009. In 2014, the
pathway was modified to encourage single-fraction treat-
ment and the use of >10 fractions was considered off
pathway. They evaluated data from 16 integrated sites
from 2003 through 2014. Overall, 12,678 unique courses
were delivered. From 2003 to 2008, the single-fraction
utilisation rate was 8%. This increased to 11% from 2009
to 2013 and to 16% in 2014. Use of >10-fraction regimens
significantly decreased from 19% in 2003–2008 to 10% in
2014. By 2014, >90% of courses were delivered with <10
fractions. Comparable efforts were undertaken regarding
hypofractioned radiotherapy for non-metastatic breast
cancer [20]. These studies demonstrate that provider-dri-
ven clinical pathways are able to standardise practice
patterns and promote change.
Conclusions
The likelihood of receiving long-course radiotherapy
was significantly higher in younger patients, those
with good performance status, limited disease extent,
and shorter time interval since diagnosis of metastatic
disease. The limited need for reirradiation after single-
fraction PRT should encourage physicians to consider
this convenient regimen, which is also suitable for
patients with reduced performance status and has
been shown in the literature to improve quality of life
across all subgroups. Single-fraction PRT contributes to
optimal resource utilisation and improves access to
treatment, especially for frail patients and those with
larger travel distance. Decision-making should take into
account that patients from remote regions need to
spend variable amounts of time away from their rela-
tives and friends. This fact becomes increasingly impor-
tant in the terminal stage of disease, when the
remaining lifetime is short and active treatment unlikely
to extend survival.
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